Co-Diagnostics' joint venture (JV) CoMira Diagnostics has completed a lease agreement for its planned manufacturing facility in the Kingdom of Saudi Arabia’s (KSA) Sudair Industrial City.

The move follows prior approval for industrial land allocation by the Saudi Authority for Industrial Cities and Technology Zones (MODON).

The leased facility comprises nearly 14,400ft² within Sudair Industrial City, serving as a designated site for manufacturing diagnostic instruments, laboratory testing equipment, and medical consumables.

It will support CoMira’s planned production of the Co-Dx PCR platform and related technologies, subject to regulatory approval and operational requirements.

The site is delivered in turnkey condition, enabling an efficient transition to operational status that aligns with Co-Diagnostics’ emphasis on capital-efficient expansion.

Co-Diagnostics CEO Dwight Egan said: “Co-Dx continues to advance our CoMira joint venture, with today's lease finalisation marking an important milestone in expanding our presence in the KSA.

“Executing the lease moves us from planning into the execution phase of development and reflects ongoing progress in localising our platform within Saudi Arabia.

“We believe this initiative supports the Kingdom's Vision 2030 goals related to healthcare infrastructure, domestic manufacturing, and supply-chain resilience.”

CoMira focuses on building local production and distribution for Saudi Arabia and the Middle East and North Africa (MENA) region, citing advantages in government procurement for locally produced healthcare solutions.

As Co-Diagnostics secures clearances from the US Food and Drug Administration (FDA) for the Co-Dx PCR platform, entry into the Saudi market may benefit from a more streamlined regulatory process.

In March 2026, Co-Diagnostics began shipping its PCR Pro instruments, Co-Dx polymerase chain reaction (PCR) mycobacterium tuberculosis (MTB) test kits for tuberculosis, and sample preparation instruments to CoSara Diagnostics, its JV in India.